News stories about Tocagen (NASDAQ:TOCA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tocagen earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3150945748372 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Separately, Zacks Investment Research downgraded Tocagen from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th.
Shares of Tocagen (TOCA) opened at $11.02 on Tuesday. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03.
Tocagen (NASDAQ:TOCA) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. equities research analysts predict that Tocagen will post -2.88 earnings per share for the current year.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Tocagen (TOCA) Stock Price” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-tocagen-toca-share-price.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.